The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NVO -2.49%), thanks to its type 2 diabetes medicine Ozempic and the Wegovy version approved for weight loss. However, Ozempic and Wegovy are facing stiff competition, notably from Mounjaro and Zepbound, marketed by Novo Nordisk's eternal rival, Eli Lilly. Further, a little-known but highly promising biotech is also looking to challenge Novo Nor ...

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo. Around 40% of people with type 2 diabetes have chronic kidney disease. It stopped the trials on 3,533 people a full year before it was mean ...

This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France.Novo Nordisk's blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday. Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compa ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024. Investors are drawn to the biotech industry not only for their potential to deliver substantial profits, but for the promise of contributing to medical breakthroughs. This can be achieved by the larger pharmaceutical giants or smaller biotechnology startups pioneering therapies like gene-editi ...

Key PointsWhile known for chicken, Tyson Foods is the largest beef producer in the United States, with over $5 billion in quarterly sales for fiscal Q1 2024.Tyson Foods sells its beef and pork under brands including Chairman's Reserve Meats, Star Ranch Angus Beef, ibp Trusted Excellence Brand, Reuben Corned Beef and Open Prairie Natural Pork.Pilgrim's Pride is one of the largest chicken producers in the world, reporting a strong Q4 2023, beating EPS estimates by 16 cents, with revenues climbing 9% YoY to $4 ...

After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (VKTX 10.60%) is now doubtlessly on many investors' radars. Soon enough, the biotech will likely try to launch a new weight loss medication capable of rivaling Novo Nordisk's (NVO 3.72%) blockbuster obesity drug, Wegovy. That means people who feel that they learned about Novo Nordisk's rapidly growing obesity care segment too late to see any upside from an investment now have anot ...

Leave Oprah alone.Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company’s board. The decision came after Winfrey announced, to considerable backlash, that she was taking a weight-loss drug to help her in her longtime battle to lose some pounds and keep them off, in addition to hiking, drinking plenty of water and other methods.The company’s stock fell in the aftermath of the news. At ...

Novo Nordisk's (NVO 3.72%) position as a hot healthcare stock got a boost from an analyst as the trading week came to a close. On a significant price target boost, the Danish pharmaceutical company's share price closed the day almost 4% higher. That was more than good enough to outpace the bellwether S&P 500 index, which rose by a relatively light 0.8%.An analyst raised his price target at a double-digit rateThe analyst giving Novo Nordisk that nice shot in the arm was Morgan Stanley's Mark Purcell. Well be ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alongsid ...